Objective
to assess the clinical outcomes of transcatheter mitral-valve repair (TMV) compared to guidelines recommended treatment (GRT) for mitral regurgitation
Study
multicentre randomised trial
Population
patients with moderate to severe mitral valve regurgitation and heart-failure
Endpoints
1) first or recurrent hospitalisation for heart failure or cardiovascular death during 24 months 2) first or recurrent hospitalisation for heart failure during 24 months
/medias/687657/25-T001_Anker_01.jpg)
/medias/687660/25-T001_Anker_02.jpg)
Conclusion
among patients with heart failure with moderate to severe mitral regurgitation transcatheter mitral-valve repair and optimal medication achieved significant better clinical outcomes (hospitalisation/death) during 24 months compared to optimal medical treatment alone
Anker et al. NEJM 2024; August 31 online
